International Journal of COPD (Feb 2021)
Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
Abstract
Shiyi Gong,1 Hao Hu,2 Kun Zhao,2 Ting Yang1 1Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Disease; Institute of Respiratory Medicine, Chinese Academy of Medical Science; Peking University Health Science Center, Beijing, People’s Republic of China; 2China National Health Development Research Center, National Health Commission of the People’s Republic of China, Beijing, People’s Republic of ChinaCorrespondence: Ting YangDepartment of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Disease; Peking University Health Science Center; Institute of Respiratory Medicine, Chinese Academy of Medical SciencePeking University Health Science Center, No. 2 Yinghua East Street, Chaoyang District, Beijing, People’s Republic of ChinaTel +86 13651380809Email [email protected]: Indacaterol/glycopyrronium (IND/GLY) is a once-daily dual bronchodilator for long-term treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy and safety of IND/GLY have been proved before, but the cost-effectiveness is unknown in China.Purpose: This study assessed cost-effectiveness of IND/GLY comparing with salmeterol/fluticasone (SAL/FLU) and tiotropium.Methods: A patient-level simulation model was established from Chinese payer perspective. Patient parameters were randomly simulated through resampling from parameter distributions based on clinical trials and China-specific cost data to represent individual level health state and health state transitions in the model. We simulated patient-level health state, costs, life years (LYs) and quality-adjusted life years (QALYs) of whole life horizon to evaluate the cost-effectiveness of IND/GLY comparing with SAL/FLU and tiotropium respectively.Results: Comparing with SAL/FLU, IND/GLY resulted in 0.384 LYs and 0.255 QALYs gained. The incremental cost-effectiveness ratio (ICER) is − 35,822 CNY/LY and the incremental cost-utility ratio (ICUR) is − 53,834 CNY/QALY for IND/GLY versus SAL/FLU. Comparing with tiotropium, IND/GLY resulted in 0.232 LYs and 0.146 QALYs gained. The ICER is 39,729 CNY/LY and the ICUR is 63,246 CNY/QALY for IND/GLY versus tiotropium.Conclusion: This study found that dual bronchodilator IND/GLY is cost-effective for stable COPD treatment in China from Chinese payer’s perspective.Keywords: chronic obstructive pulmonary disease; COPD, dual bronchodilator, cost-effectiveness analysis, China
